Table 2. Correlations between the expression of PD-L1 and clinicopathological characteristics in OCCCs.
| Variables | Tumoral PD-L1 expression | |||
|---|---|---|---|---|
| Low expression | High expression | p-value | ||
| Age (yr) | 0.260 | |||
| ≤55 | 39 (57.4) | 37 (68.5) | ||
| >55 | 29 (42.6) | 17 (31.5) | ||
| Stage | 0.020 | |||
| Early (I–II) | 48 (70.6) | 27 (50.0) | ||
| Advanced (III–IV) | 20 (29.4) | 27 (50.0) | ||
| BMI | 0.068 | |||
| ≤25 | 29 (42.6) | 32 (59.3) | ||
| >25 | 39 (57.4) | 22 (40.7) | ||
| Menopause status | 0.264 | |||
| Premenopausal | 23 (33.8) | 24 (44.4) | ||
| Postmenopausal | 45 (66.2) | 30 (55.6) | ||
| Pretreatment CA125 (U/mL) | 0.699 | |||
| <244 | 32 (53.3) | 23 (48.9) | ||
| ≥244 | 28 (46.7) | 24 (51.1) | ||
| Ascitic fluid | 0.016 | |||
| Negative | 45 (68.2) | 23 (45.1) | ||
| Positive | 21 (31.8) | 28 (54.9) | ||
| Tumor site | 0.245 | |||
| Unilateral | 58 (85.3) | 41 (75.9) | ||
| Bilateral | 10 (14.7) | 13 (24.1) | ||
| Tumor volume (cm) | 0.854 | |||
| <10 | 28 (41.2) | 21 (38.9) | ||
| ≥10 | 40 (58.8) | 33 (61.1) | ||
| Sensitivity to chemotherapy | 0.045 | |||
| Sensitive | 50 (74.6) | 31 (57.4) | ||
| Insensitive | 17 (25.4) | 23 (42.6) | ||
| Recurrence status | 0.038 | |||
| Relapse | 25 (36.8) | 30 (55.6) | ||
| No relapse | 43 (63.2) | 24 (44.4) | ||
BMI, body mass index; OCCC, ovarian clear cell carcinoma; PD-L1, programmed death-ligand 1.